pefni t26 low
TRANSCRIPT
-
8/12/2019 Pefni t26 Low
1/31
:
-:
:
: ;
| 26 | 2012 / - 2013
(.....)
15
018673
-
8/12/2019 Pefni t26 Low
2/31
-
8/12/2019 Pefni t26 Low
3/31
4
6 | 6 |
14 | .....
14 | 14 |
15 | O -
16 |
16 | ...- / -: - (bio-similar)
17 |
22 | - 22 |
26 |
26 |
28 | - 28 | Generics Conference 2013
30 | 30 | / :
,
18 |
18 | 19 | 20 |
& :
| 26 2012 / - 2013
.....
: : . : : : : : , ,
.....
99, 115 27, ./fax: 210 7753104e-mail: [email protected]://www.pefni.gr
I
-
, , , , ,
.
:
,
:
:
Pressious Arvanitidis
-
8/12/2019 Pefni t26 Low
4/31
-
8/12/2019 Pefni t26 Low
5/31
6
.
, 13.02.2013..: 10/.. . 16980
/ / .. / . : 17. : 10187 / : . : 213 2161217, 210 5247421
: - , , , , -, , , - ,
:1. 20 4024/11 (
226/27.10.11/) , - - , - - 2012-2015,
. 6 32 .4038/12 ( 14/02.02.12/), . 2 16 . 2 32 . 4058/12 (63/22.03.12/) . 1 13 45 . 4071/12 ( 85/11.04.12/), 30 . 4052/12 ( 41/01.03.12/)
2. 13 . 3204/03 ( 296/2003, . )
3. - ( 3486//31.12.12, 3499//31.12.12, 3510//31.12.12, 3515//31.12.12 3521//31.12.12)
4. . 10/.. .123582/28.12.2012 ( 3562/'/
31.12.12 , -, , , , / , , - , ...: -
- (11.420.000) , , -, , , -, , , - 2013, :
, , , , , , , ,
- - , . .
. . . 5/. 27300/09.03.13 02.04.13 (www.pefni.gr).
-
8/12/2019 Pefni t26 Low
6/317 2012 / - 2013
-
8/12/2019 Pefni t26 Low
7/318
-
8/12/2019 Pefni t26 Low
8/319 2012 / - 2013
-
8/12/2019 Pefni t26 Low
9/3110
-
8/12/2019 Pefni t26 Low
10/31
-
8/12/2019 Pefni t26 Low
11/3112
20 - 150 -. . : .. . , , , , , , , .
-
8/12/2019 Pefni t26 Low
12/3113 - - 2013
-
8/12/2019 Pefni t26 Low
13/31
.....
14
25/2/2013 (. www.pefni.gr) , - . , 20 -, ! , , , ,
.
. .: . 9849/25/1/2012 - 05.02.2013 . , , - , - .
, . 4052/12, - 01.01.2013. , -, 21.01.2013, .
, - , -
, - . , - , , -
! - , .
-
8/12/2019 Pefni t26 Low
14/3115 2012 / - 2013
.....
, , - , , . , , - . . - .
O
, , - : - , - . e-mail :
| | [email protected] | | [email protected] | . | [email protected] .
-
8/12/2019 Pefni t26 Low
15/31
16
:1. -
() 2009.2. -
EMA Guidelines CHMP/437/042005.3. EMA/837805/2011: Questions and answers, 27 September
2012, European Medicines Agency.4. EU Commission Directive 2012/52/EU, Official Journal of
the EU, l356/65, 22.12.20125. 3/. 82161 ( 2374/
'/2012).
6. 3()/. 104744 ( 2912/'/30.10.2012).
7. 4 ( 3057/'/18.11.2012). - :)
, -
) ,
:1. -
- - , . .
2. - - , .
, - - , - . .
.. .
--: - (bio-similar)
(. Filgrastim) . - () / . , () - . .
-
8/12/2019 Pefni t26 Low
16/3117 2012 / - 2013
. 2010 - . , 2012, - 1995. , , :
. - . . .
(European Medicine Agency) - (Good Pharmacovigilance Practice, GVP) . -
, , - (www.emea.europa.eu) :me>Regularory>Human medicines>Pharmacovigilance. -: . -
. .
. , , () 2013. - -, , - .O , , (, .
11, 08.03.13): - , . , 197.000 - (U) - (Adverse Drug Reaction, ADRs). - ,: , , , , -
. - 5.000 , 2,5 . - , , - , - . !
-
8/12/2019 Pefni t26 Low
17/3118
108/1993, - () , . -
108/1993( ' 50/93) , , , 6//6551/93 ( 419/93) , - , - . , :
1. , - , .
2. ( - ), - , , 8 108/1993 ( 200..) -.
3.
.4.
- .
5. - .
6. -, , .
7. :
()
(-) :)
-
) ,
) / -
) , , -
, - , , . - - - .
-
8/12/2019 Pefni t26 Low
18/3119 2012 / - 2013
... . / -
............................................................................................................................................................................................................................................................................................................................() .. .........() .. .........() .. ......... ......................................................................................................................................................................................................................................................................................................................................................................................... ........................................................................................................................................................................................................................................................................................................................................... ....................................................................................................................................................................................................................................................................................................................() ........................(.) ............. :1) . . .. .. .. ..
. . .. .. .. .. .. .. . / /- /2) .........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................
3) ..................................................................................................................... .. ( 200 ..)4) .............................................................................................................................................................................................................................................................................................5) & .....................................................................................................................................................................................................................................................................................................................6) , .......................................................................................................................................................................................................................................................................................................................................7) ................................................................................................................................................................................................................................................................................................................8) :
) / - - ......................................................................................................................................................................................................... ( 30 ..) ) ........................................................................................................................................................................................................................................................................................................................................................( 40 ..) ) - .................................................................................................................................................................................................................................................................................... ( 30 ..) ) - ............................................................................................................................................................................................................................................................... ( 30 ..)
) ............................................................................................................................................................................................................................................................................................................................
( 10 ..)) ................................................................................................................................................................................................................................................................................................................................... ( 5 ..) ) ....................................................................................................................................................................................................................................... ( 45 ..) ) ......................................................................................................................................................................................................................................................... ( 15 ..) ( ............ ........... ............ ............) ) ................................................................................................................................................................................................................................................................................................................... ( 30 ..) ) . ......................................................................................................................................................................................................................................................................................) - , , . .................................................................................................................
9) .....................................................................................................................................................................................................................10) ........................ & ......................11) 3 : 1 ( 0,005 .) ......, 1 30 . ...... & 1 & ......12) & : , , , , . 5-1000cc, , . ...........................................................................................................................13) .........................................................................................................................................................................................................................................................................................................................................14) ..................................................................................................................................................................................................................................................................................................................................................15) ...............................................................................................................................................................................................................................................................................................16) .........................................................................................................................................................................................................................................................................................................................................................17) ...........................................................................................................................................................................................................................................................................................................................................18) & : ) .....................................................................................................................................................................................................................................
) ........... ) ............ ) & . 10 & . 11 108/1993 & ..................................................) . 1729/87...............................................................................................................................................................................................................................................................
19) ................................................................................................................................................................................................................................................................................................................................................20) ................................................................................................................................................................................................................................................................................21) ........................................................................................................................................................................................................................................................................
(2) & :
/
-
8/12/2019 Pefni t26 Low
19/3120
. 21 . - ISO . 108/1993 -
, . .
No
7 .. (06.09.2012), - , - - (04.10.2012), - , .. 108. 05.12.2012, - , .
& / & . -
. /: . 11, . : 73100.: . , .: 28213 44213, Fax: 28210 20105/ : [email protected]
: " "
:1. . 3852/2010 ( 87//07-06-2010) / - .2. .. 149/2010 ( 242//27-12-2010) .
3. ' . . 860/27-01-2011
- . .4. .. 108 ( 50//07-04-1993) , .5. ' . . 37836/24-08-1995 ( 695/. -/13-09-1996 .6. 05-12-2012 .
" ". - , .
..
1 2 3
4
1 2 3 - , 4
, 05-12-2012 : 5135
-
8/12/2019 Pefni t26 Low
20/3121 - - 2013
,
. . . . .
No
.N. No
, - .. 108/93 . 5607/1932 . 2071/1992 - (, , , ). 1 17.08.2012 . 15906 . - :1) - ( / )2) ( ) 3) (- )
( )4) ( )5) (- - ). (, , ) ( ). ISO 9001:2008 ( , ). - (2007).
. . 13656/26-10-2012. - - ( , - , , ) ( 2004). - , - . -
- - - ( , , ( -, ). , , ,
- (.. , ), - .. - , , , - .), - group ( / ) . - .
. , /
. -
&
: &
. / : , . : 67100
: . , : 25413
50136
Fa x: 2541083367, E -ma i l: dd yge ias. xan t h i @pa
m t hgo v.gr
:
&
-
, : 1 )
: ) . 3852/2010
) .. 144/2010
) .. 108/1
993 ,
. 2 ) . . 2824/21 -2 -
2011
,
. .
-
( ..
). 3 ) 15 -4 -2011
/ &
.
-
.
, 12 2011
: . . 902
-
8/12/2019 Pefni t26 Low
21/3122
-
- , , ,
-. , . , SWEDRES , DANMAP NETHMAP . 20 - (WHONET GREECE), - .
W - - ., -. - . -
(, ), WHONET, - .
-
Pharm, MPH, PhD,
-
-
8/12/2019 Pefni t26 Low
22/3123 2012 / - 2013
( , , ). - 2010 - (, , ) - . 14 - ( 2011). - ( , )
1 2 2011. - 22 - ( 2012) 1 ( 2012).
:,
ABC calc
,
, . (Defined Daily Dose DDD). DDD ( , - , - 70 - ATC - - - . -
-
. DDD - . - DDD . - , .
, DDD/1000 -, - DDD/100 . - (AntibioticConsumption Calculator ABC calc) . - Statens Serum Institute , Dr. Dominique Monnet, Danish Integrated Antimicrobial Resistance Monitoringand Research Program (DANMAP). - Microsoft Excel, - :
-
-
8/12/2019 Pefni t26 Low
23/3124
:1. D (Name of the product)
. - ... Ciprofloxacin, - - , ..Ciproxin 200mg inj., Ciproxin 400mg inj., Ciproxin 500mg
tabl, Nafloxin 200mg inj., Ciprofal 400mg ...2. E
.3. F -
.4. L -
- (.. ). - ( ) DDD ( ).
5. -
DDD/100 . % ( Occupancy Index), , - :
,
(-, ), (.. -, 1, 2, 3, 4 ). , L , - Excel, ATC . , (copy) (paste)
Excel ABC calc, ( - ) . Excel ABC calc, ATC ( ), DDD.
- ().
(2013) -
(1/. 30674-29.03.2013). - ( ) -, - -,
-
-
8/12/2019 Pefni t26 Low
24/3125 2012 / - 2013
DDD/100 .
- . - - ABC calc - DDD/100 . -
- , - "" - - ( - ), - , , - .
SWEDERSS: http://www.swab.nl/swab en. strama.se DANMAP: http://www.danmap.org/ NETHMAP: http://www.swab.nl/swab
1. , , . : - . 15 . 13-15
2011, , Royal Olympic. - , 14 2011.
2. Markogiannakis A, Gennimata D, Goulas V, Tzortzo-poulou K, Aggelopoulou V, Makridaki D. Antibioticconsuption among six general hospitals: resultsfrom a Greek surveillance network. 22nd ECCMID. 31March-3 April 2012, London. Abstract No R2577.
3. , , , - , , . -: - 2011. 1 . 27-30 2012, . Poster No. AA053.
1. DL Monnet. Measuring antibiotic resistance: the way forward.Clin Microbiol Infect 2007; 44: 671-673.2. DL Monnet DL, LK Archibald, L Phillips, FC Tenover, JE MCGowan, RP Gaynes. Antimicrobial use and resistance in eight US hospitals:
complexities of analysis and modeling. Intensive Care Antimicrobial Resistance Epidemiology Project and National Nosocomial Infections
Surveillance System Hospitals. Infect Control Hosp Epidemiol 1998;19: 388-94.3. CE Curtis. Indicators for monitoring of antimicrobial use. J Infect Prevent2010; 11: 124-1264. DN Fish, SC Piscitelli and LH Danziger. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient
characteristics in 173 studies.Pharmacotherapy 15 (1995): 279-291.5. AC Fluit, J Verhoef, FJ Schmitz et al. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from
patients in intensive care units of 25 European university hospitals part icipating in the European arm of the SENTRY Antimicrobial SurveillanceProgram 1997-1998.Eur J Clin Microbiol Infect Dis20 (2001): 617-625.
6. SK Fridkin, JR Edwards, FC Tenover, RP Gaynes, JE McGowan Jr. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project; NationNosocomial Infections Surveillance (NNIS) System Hospitals. Antimicrobial resistance prevalence rates in hospital antibiograms reflectprevalence rates among pathogens associated with hospital-acquired infections. Clin Infect Dis 2001; 33: 324-330.
7. RP Gaynes. The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals.Infect Dis Clin North Am11(1997): 757-765.
8. C Gentry, DJ Flournoy and R Reinert. Analysis of antimicrobial resistance among gram-negative bacilli and antimicrobial use in intensive careunit patients for 5 years in a Veterans Affairs medical center. Am J Infect Control 30 (2002): 411-416.
-
-
8/12/2019 Pefni t26 Low
25/31
26
;
(European Association of Hospital Pharmacists -) . 14.02.2013 (. www.pefni.gr) . - - 18o 13 15 2013. Programme Book .
;
2012 - ( EAHP - , ), 2013 . , EAHP
( - ) - , , -, . . - , , - , , , , - , -
- . - . - -; EAHP ( - 32 -), - 2012, , -
-
8/12/2019 Pefni t26 Low
26/3127 2012 / - 2013
,
- , ., 2012 - , , - . , ., , - , -, . - - , -
EAHP -
. EAHP - . - , . , - . EAHP
, -, - . , EAHP . , - .
H
13-16 2013
. ,
.
.. .
.....
-
8/12/2019 Pefni t26 Low
27/31
-
28
Generics Conference 2013
Generics Conference 2013 6 2013 AthenaeumInterContinental Ethos Media S.A. - Pharma & Health Business, - (...), - (....) (...). 26 400 ( , , -), - , , - . : . . - .
- . : , , . : , ,. -.
15% ,
70%. - , . - - : http://www.moneyconferences.com/uploads/file/GENERICS_CONF2013/Apologismos/index_local.html - () ,. , - - : , , -. ,, Pharma & Health Business . -, , - , ,, , , D , , (). -
, - . , 2 3 - . !. ,
-
8/12/2019 Pefni t26 Low
28/31
, . - . - - ,
. - - , , , - . , - , . . -
, o - 1,1 800. , - , - , . - http://www.moneyconferences.com/conference.asp?catid=1964
- , - . -, . , . . . .
29 2012 / - 2013
-
16 31 - 3 2013,
7 - Mamagement 14-15 2013, A , .
;
35th ESPEN Congress 2013 ON CLINICAL NUTRITION AND METABOLISM31 August - 3 September 2013, Leipzig, GermanyTearing down barriers nutrition brings people together
-
8/12/2019 Pefni t26 Low
29/3130
,
...
, , , , ...
;
, , , , . , . - - ;
: ()ISBN: 978-960-04-4380-6 | . 312 | 2013
1961. - , . . (, 1991 - , 2003), (, 1995), (, 1997), (, 2001), (, 2006) , (, 2013).
-
8/12/2019 Pefni t26 Low
30/31
-
8/12/2019 Pefni t26 Low
31/31